Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioblastoma 40Breast Neoplasms 23Gliosarcoma 22Esophageal Neoplasms 21Prostatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 19Pancreatic Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Rectal Neoplasms 13Glioma 13Brain Neoplasms 13Uterine Cervical Neoplasms 12Neoplasms 12Lung Neoplasms 11Head and Neck Neoplasms 11Melanoma 10Astrocytoma 10Sarcoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Central Nervous System Neoplasms 8Stomach Neoplasms 7Lymphoma, Follicular 6Esophageal Squamous Cell Carcinoma 6Endometrial Neoplasms 6Adenocarcinoma Of Esophagus 6Oropharyngeal Neoplasms 5Neoplasm Metastasis 5Lymphoma 5Carcinoma 5Burkitt Lymphoma 5

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Bladder Urothelial Carcinoma × Radiation × Clear all
NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 10 charts
Genitourinary

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡